Browsing by Author Regan, Meredith M.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 21  next >
Issue DateTitleAuthor(s)Citation
2014Adjuvant exemestane with ovarian suppression in premenopausal breast cancerCoates, Alan; Burstein, Harold J.; Colleoni, Marco; et al, Various; Fleming, G. F.; Gomez, Henry; Lang, Istvan; Pagani, Olivia; Perez, E. A.; Regan, Meredith M.; Tondini, Carlo; Walley, B; School of Public Health: Public HealthAdjuvant exemestane with ovarian suppression in premenopausal breast cancer, New England Journal of Medicine, vol.371, 2, 2014,pp 107-118
2008Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trialCoates, Alan; Altermatt, Hans J; Braye, Stephen; Castiglione-Gertsch, Monica; Del Curto, Barbara; Dell'Orto, Patrizia; Gelber, Richard D. (Prof); Goldhirsch, A; Gusterson, Barry; Henriksen, Katrine L; Lacroix-Triki, Magali; Lykkesfeldt, Anne E; Mastropasqua, Mauro G.; Mery, Eliane; Price, K. N.; Rasmussen, Brigitte B; Regan, Meredith M.; Thurlimann, Beat; Viale, Giuseppe; School of Public Health: Public HealthAdjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial, The Lancet, vol.9, N/A, 2008,pp 23-28
2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyCoates, Alan; Chirgwin, Jacquie H; Colleoni, Marco; Forbes, John F.; Gelber, Richard D. (Prof); Giobbie-Hurder, Anita; Goldhirsch, Aron (Prof); Lang, Istvan; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Pienkowski, Tadeusz; Price, Karen N.; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, Beat; Wardley, Andrew; School of Public Health: Public HealthAnalyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study, Journal of Clinical Oncology, vol.29, 9, 2011,pp 1117-1124
2011Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-upCoates, Alan; Ejlertsen, Bent; Forbes, John F.; Gelber, Richard; Giobbie-Hurder, Anita; Goldhirsch, Aron; Lang, Istvan; Mauriac, Louis; Neven, Patrick; Price, Karen N.; Rabaglio, Manuela; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, B.; Wardley, Andrew; School of Public Health: Public HealthAssessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up, Lancet Oncology, vol.12, 12, 2011,pp 1101-1108
2008Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors-International Breast Cancer Study GroupCoates, Alan; Braye, Stephen; Brown, Robert; Castiglione-Gertsch, Monica; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Golouh, Rastko; Grigolato, Piergioranni; Gusterson, Barry A.; Kovacs, Aniko; Maiorano, Eugenio; Mastropasqua, Mauro G.; Ohlschlegel, Christian; Perin, Tiziana; Pillay, Komala; Price, Karen N.; Regan, Meredith M.; Rusca, Tiziana; Viale, Giuseppe; School of Public Health: Public HealthChemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors-International Breast Cancer Study Group, Journal of Clinical Oncology, vol.26, 9, 2008,pp 1404-1410
2010Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast CancerCoates, Alan; Cole, Bernard; Colleoni, Marco; Crivellari, Diana; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Gusterson, Barry; Maiorano, Eugenio; Mastropasqua, Mauro G.; Price, Karen N.; Regan, Meredith M.; Viale, Giuseppe; School of Public Health: Public HealthClassical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer, Journal of Clinical Oncology, vol.28, 18, 2010,pp 2966-2973
2017Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: An exploratory analysis of TEXT and SOFTCoates, Alan; Abdi, Ehtesham; Colleoni, Marco; Fleming, G. F.; Francis, P A; Gelber, Richard; Goldhirsch, A; Gomez, Henry; Lang, Istvan; Pagani, Olivia; Parmar, Vani; Pinotti, Graziella; Regan, Meredith M.; Ruhstaller, Thomas; Salim, Muhammad; Spazzapan, Simon; Tondini, Carlo; Walley, B. A.; NH&MRC Clinical Trials CentreConcurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: An exploratory analysis of TEXT and SOFT, Annals of Oncology, vol.28, 9, 2017,pp 2225-2232
2012CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialCoates, Alan; Biasi, Maria Olivia; Bouzyk, Mark; Dell’Orto, Patrizia; Ditzel, Henrik; et al, various; Kammler, Roswitha; Leyland-Jones, Brian; Lyng, Maria; Pagani, Olivia; Regan, Meredith M.; Tang, Weining; Thurlimann, Beat; School of Public Health: Public HealthCYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial, Journal of the National Cancer Institute, vol.104, 6, 2012,pp 441-451
2011Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX.Coates, Alan; Aebi, S; Braun, D; Castiglione-Gertsch, M; Crivellari, Diana; Gelber, Richard; Goldhirsch, A; Gusterson, B. A.; Karlsson, P; Lindtner, Jurii; Price, K. N.; Rabaglio, Manuela; Regan, Meredith M.; Simoncini, Edda; Snyder, Raymond; Sun, Z; Viale, Giuseppe; School of Public Health: Public HealthDifferential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX., Annals of Oncology, vol.22, 9, 2011,pp 1981-1987
2012Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 TrialCoates, Alan; Bonnefoi, Herve; Ejlertsen, Bent; et al, Various; Ewertz, Marianne; Forbes, John F.; Gray, Kathryn P; Paridaens, R.J.; Price, Karen N.; Rabaglio, Manuela; Regan, Meredith M.; Thurlimann, Beat; School of Public Health: Public HealthObesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial, Journal of Clinical Oncology, vol.30, 32, 2012,pp 3967-3975
2008p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.Coates, Alan; Castiglione-Gertsch, Monica; Gianni, Lorenzo; Goldhirsch, Aron; Gusterson, Barry; Maffini, Fausto; Mastropasqua, M; Monti, F; Panzini, Ilaria; Price, Karen; Ravaioli, A; Regan, Meredith M.; Spataro, Vito J.; Viale, Giuseppe; School of Public Health: Public Healthp27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer., Annals of Oncology, vol.19, 4, 2008,pp 660-668
2008Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerCoates, Alan; Colleoni, Marco; et al, various; Golouh, Rastko; Maffini, Fausto; Maiorano, Eugenio; Mastropasqua, Mauro G.; Perin, Tiziana; Price, K N; Regan, Meredith M.; Viale, Giuseppe; School of Public Health: Public HealthPredictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer, Journal of the National Cancer Institute, vol.100,(3),2008,pp 207-212
2008Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?Coates, Alan; et al, Various; Fleming, G. F.; Francis, P A; Pagani, Olivia; Perez, E. A.; Price, K N; Regan, Meredith M.; Thurlimann, Beat; Torrisi, R; Walley, B; School of Public Health: Public HealthPremenopausal endocrine-responsive early breast cancer: who receives chemotherapy?, Annals of Oncology, vol.19, 7, 2008,pp 1231-1241
2012Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trialsCoates, Alan; Gelber, Richard D. (Prof); Gelber, S.; Goldhirsch, Aron; Huober, J; Ohlschlegel, Christian; Price, K. N; Regan, Meredith M.; Thurlimann, Beat; Viale, Giuseppe; School of Public Health: Public HealthPrognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials, Annals of Oncology, vol.23, 11, 2012,pp 2843-2851
2010Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyCoates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Gelber, Richard D. (Prof); Goldhirsch, A; Maiorano, Eugenio; Mastropasqua, Mauro G.; Price, Karen; Regan, Meredith M.; Viale, Giuseppe; School of Public Health: Public HealthPrognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy, Breast Cancer Research and Treatment, vol.121, 1,pp 211-218
2007Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Women With Early Breast Cancer: Results From the BIG 1-98 Collaborative GroupsCoates, Alan; Dell'Orto, Patrizia; et, al; Maiorano, Eugenio; Mastropasqua, Mauro G.; Neven, Patrick; Orosz, Zsolt; Raffoul, Johnny; Rasmussen, Brigitte B; Regan, Meredith M.; Viale, Giuseppe; School of Public Health: Public HealthPrognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Women With Early Breast Cancer: Results From the BIG 1-98 Collaborative Groups, Journal of Clinical Oncology, vol.25,(25),2007,pp 3846-3852
2008Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With LetrozoleCoates, Alan; Braye, Stephen; Dell'Orto, Patrizia; et al, Various; Giobbie-Hurder, Anita; MacGrogan, Gaetan; Maiorano, Eugenio; Mastropasqua, Mauro G.; Ohlschlegel, Christian; Regan, Meredith M.; Viale, Giuseppe; School of Public Health: Public HealthPrognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole, Journal of Clinical Oncology, vol.26, 34, 2008,pp 5569-5575
2012Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXCoates, Alan; O'Toole, Sandra; Castiglione-Gertsch, Monica; Gelber, Richard; Goldhirsch, Aron (Prof); Gusterson, Barry; Millar, E. K. A.; Molloy, T; Musgrove, Elizabeth A.; Regan, Meredith M.; Sun, Zhuoxin; Sutherland, Robert L.; Viale, Giuseppe; School of Public Health: Public Health; Central Clinical School: PathologyPrognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX, Breast Cancer Research, vol.14, 6, 2012,pp 1-12
2006Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays.Coates, Alan; Brown, Bob; Carbone, Antonino; et, al; Golouh, Rastko; Langman, Gerald; Maiorano, Eugenio; Mastropasqua, Mauro G.; Regan, Meredith M.; Suurküla, Mart; Viale, Giuseppe; School of Public Health: Public HealthRe-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays., Journal of the National Cancer Institute, February 2005, vol.98,(21),2006,pp 1571-1581
2017Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trialsCoates, Alan; Bernhard, J; et al, Various; Francis, Prudence; Gomez, Henry; Luo, Weixiu; Pagani, Olivia; Regan, Meredith M.; Ribi, Karen; Saha, Poornima; Walley, Barbara; NH&MRC Clinical Trials CentreTreatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials, Journal of Clinical Oncology, vol.35, 27, 2017,pp 3113-3122